{
 "cells": [
  {
   "cell_type": "markdown",
   "id": "6d8f3a76",
   "metadata": {},
   "source": [
    "\n",
    "## HyDE RAG: Medical Research Assistant\n",
    "Real-world use case: Helping oncologists and researchers find relevant medical literature\n",
    "by first generating hypothetical ideal research papers, then using them to guide retrieval.\n",
    "\n",
    "Use Case: A medical researcher asks: \"What are the latest immunotherapy approaches for treating \n",
    "pediatric acute lymphoblastic leukemia with resistance to conventional chemotherapy?\"\n",
    "\n",
    "Instead of directly searching with this query, HyDE first generates what an ideal research paper\n",
    "would look like, then uses that hypothetical document to find actual relevant papers.\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 1,
   "id": "a60a2045",
   "metadata": {},
   "outputs": [],
   "source": [
    "import os\n",
    "import json\n",
    "from typing import List, Dict, Any\n",
    "from langchain_core.prompts import ChatPromptTemplate\n",
    "from langchain_community.vectorstores import FAISS\n",
    "from langchain_community.document_loaders import PyPDFLoader\n",
    "from langchain.text_splitter import RecursiveCharacterTextSplitter\n",
    "from langchain_tavily import TavilySearch\n",
    "from pydantic import BaseModel, Field\n",
    "from typing_extensions import TypedDict\n",
    "import numpy as np\n",
    "from datetime import datetime\n",
    "from langchain_google_genai import GoogleGenerativeAIEmbeddings\n",
    "from langchain_groq import ChatGroq   "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "id": "dfeaff72",
   "metadata": {},
   "outputs": [],
   "source": [
    "from dotenv import load_dotenv\n",
    "load_dotenv()\n",
    "\n",
    "# Set up environment variables\n",
    "os.environ[\"GOOGLE_API_KEY\"] = os.getenv(\"GOOGLE_API_KEY\")\n",
    "os.environ[\"TAVILY_API_KEY\"] = os.getenv(\"TAVILY_API_KEY\")\n",
    "os.environ[\"GROQ_API_KEY\"]=os.getenv(\"GROQ_API_KEY\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "id": "5e83c26d",
   "metadata": {},
   "outputs": [],
   "source": [
    "class MedicalQuery(BaseModel):\n",
    "    \"\"\"Structure for medical research queries.\"\"\"\n",
    "    \n",
    "    condition: str = Field(description=\"Primary medical condition or disease\")\n",
    "    treatment_type: str = Field(description=\"Type of treatment being researched\")\n",
    "    patient_population: str = Field(description=\"Target patient demographics\")\n",
    "    urgency: str = Field(description=\"Research urgency: 'routine', 'urgent', 'critical'\")\n",
    "\n",
    "class HyDEMedicalState(TypedDict):\n",
    "    \"\"\"State management for HyDE medical research workflow.\"\"\"\n",
    "    \n",
    "    original_query: str\n",
    "    parsed_query: MedicalQuery\n",
    "    hypothetical_document: str\n",
    "    retrieved_documents: List[Dict[str, Any]]\n",
    "    final_response: str\n",
    "    search_embeddings: List[float]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 15,
   "id": "1e0adefc",
   "metadata": {},
   "outputs": [],
   "source": [
    "class HyDEMedicalRAG:\n",
    "    \"\"\"\n",
    "    HyDE RAG system specifically designed for medical research queries.\n",
    "    \n",
    "    This system is particularly valuable for medical research because:\n",
    "    1. Medical queries are often complex and multi-faceted\n",
    "    2. Ideal research papers have specific structures (abstract, methods, results, conclusions)\n",
    "    3. Medical terminology can be domain-specific and benefit from hypothetical context\n",
    "    \"\"\"\n",
    "    \n",
    "    def __init__(self):\n",
    "        self.llm =ChatGroq(model=\"Gemma2-9b-It\")\n",
    "        self.embeddings = GoogleGenerativeAIEmbeddings(model=\"models/embedding-001\",google_api_key=os.getenv(\"GOOGLE_API_KEY\"))\n",
    "        self.web_search = TavilySearch(k=5)\n",
    "        \n",
    "        # Build medical knowledge base\n",
    "        self.medical_vectorstore = self._build_medical_knowledge_base()\n",
    "        \n",
    "        # Initialize prompts\n",
    "        self._setup_prompts()\n",
    "    \n",
    "    def _build_medical_knowledge_base(self):\n",
    "        \"\"\"\n",
    "        Build a medical knowledge base with sample research papers.\n",
    "        In a real implementation, this would contain thousands of medical papers.\n",
    "        \"\"\"\n",
    "        print(\"üìö Building medical knowledge base...\")\n",
    "        \n",
    "        # Sample medical research papers content\n",
    "        sample_papers = [\n",
    "            {\n",
    "                \"title\": \"CAR-T Cell Therapy for Pediatric Acute Lymphoblastic Leukemia: Recent Advances\",\n",
    "                \"content\": \"\"\"\n",
    "                Abstract: Chimeric Antigen Receptor T-cell (CAR-T) therapy has revolutionized treatment \n",
    "                for pediatric acute lymphoblastic leukemia (ALL). This study reviews recent advances in \n",
    "                CAR-T cell therapy, including novel antigen targets, enhanced safety profiles, and \n",
    "                improved persistence. Methods: We analyzed 156 pediatric patients treated with \n",
    "                tisagenlecleucel between 2019-2024. Results: Complete remission rates of 89% were \n",
    "                achieved in relapsed/refractory B-cell ALL patients. Conclusion: CAR-T therapy \n",
    "                represents a paradigm shift in pediatric oncology with continued improvements in \n",
    "                efficacy and safety profiles.\n",
    "                \"\"\",\n",
    "                \"authors\": \"Smith, J.A., et al.\",\n",
    "                \"journal\": \"Journal of Pediatric Oncology\",\n",
    "                \"year\": \"2024\",\n",
    "                \"keywords\": [\"CAR-T\", \"pediatric\", \"ALL\", \"immunotherapy\"]\n",
    "            },\n",
    "            {\n",
    "                \"title\": \"Blinatumomab in Chemotherapy-Resistant Pediatric B-ALL: A Multicenter Study\",\n",
    "                \"content\": \"\"\"\n",
    "                Abstract: Blinatumomab, a bispecific T-cell engager (BiTE), has shown promising results \n",
    "                in pediatric patients with chemotherapy-resistant B-cell acute lymphoblastic leukemia. \n",
    "                This multicenter study evaluates safety and efficacy outcomes. Methods: 78 pediatric \n",
    "                patients with relapsed/refractory B-ALL received blinatumomab therapy. Results: \n",
    "                Overall response rate was 73% with manageable toxicity profile. Cytokine release \n",
    "                syndrome occurred in 23% of patients. Conclusion: Blinatumomab provides an effective \n",
    "                bridge to transplantation for high-risk pediatric ALL patients.\n",
    "                \"\"\",\n",
    "                \"authors\": \"Johnson, M.B., et al.\",\n",
    "                \"journal\": \"Blood Cancer Research\",\n",
    "                \"year\": \"2024\",\n",
    "                \"keywords\": [\"blinatumomab\", \"BiTE\", \"pediatric\", \"chemotherapy-resistant\"]\n",
    "            },\n",
    "            {\n",
    "                \"title\": \"Novel Immunotherapeutic Approaches for Pediatric Hematological Malignancies\",\n",
    "                \"content\": \"\"\"\n",
    "                Abstract: The landscape of pediatric hematological malignancy treatment has evolved \n",
    "                significantly with novel immunotherapeutic approaches. This review examines emerging \n",
    "                strategies including checkpoint inhibitors, cellular therapies, and combination \n",
    "                approaches. Methods: Comprehensive literature review of immunotherapy trials in \n",
    "                pediatric patients from 2020-2024. Results: Combination immunotherapy strategies \n",
    "                show enhanced efficacy with acceptable toxicity profiles. Conclusion: \n",
    "                Immunotherapy represents the future of pediatric cancer treatment with personalized \n",
    "                approaches becoming increasingly viable.\n",
    "                \"\"\",\n",
    "                \"authors\": \"Chen, L.K., et al.\",\n",
    "                \"journal\": \"Pediatric Hematology Today\",\n",
    "                \"year\": \"2024\",\n",
    "                \"keywords\": [\"immunotherapy\", \"pediatric\", \"hematological\", \"malignancies\"]\n",
    "            }\n",
    "        ]\n",
    "        \n",
    "        # Convert to documents and create embeddings\n",
    "        documents = []\n",
    "        for paper in sample_papers:\n",
    "            doc_content = f\"Title: {paper['title']}\\nContent: {paper['content']}\\nAuthors: {paper['authors']}\\nJournal: {paper['journal']}\\nYear: {paper['year']}\\nKeywords: {', '.join(paper['keywords'])}\"\n",
    "            documents.append(doc_content)\n",
    "        \n",
    "        # Create FAISS vectorstore\n",
    "        if documents:\n",
    "            vectorstore = FAISS.from_texts(documents, self.embeddings)\n",
    "            return vectorstore.as_retriever(search_kwargs={\"k\": 3})\n",
    "        \n",
    "        return None\n",
    "    \n",
    "    def _setup_prompts(self):\n",
    "        \"\"\"Initialize all the prompts used in the HyDE workflow.\"\"\"\n",
    "        \n",
    "        # Step 1: Query Analysis Prompt\n",
    "        self.query_analysis_prompt = ChatPromptTemplate.from_messages([\n",
    "            (\"system\", \"\"\"You are a medical research analyst. Parse the medical query and extract:\n",
    "            1. Primary condition/disease\n",
    "            2. Treatment type being researched\n",
    "            3. Target patient population\n",
    "            4. Research urgency level\n",
    "            \n",
    "            Return a structured analysis.\"\"\"),\n",
    "            (\"human\", \"Medical Query: {query}\")\n",
    "        ])\n",
    "        \n",
    "        # Step 2: Hypothetical Document Generation Prompt\n",
    "        self.hypothetical_doc_prompt = ChatPromptTemplate.from_messages([\n",
    "            (\"system\", \"\"\"You are a medical research expert. Generate a hypothetical research paper \n",
    "            that would perfectly answer the given medical query. The paper should include:\n",
    "            \n",
    "            1. A compelling title\n",
    "            2. Abstract with background, methods, results, and conclusions\n",
    "            3. Key findings that directly address the query\n",
    "            4. Relevant medical terminology and concepts\n",
    "            5. Specific data points and statistics (realistic but hypothetical)\n",
    "            \n",
    "            Make it sound like a real research paper that would be published in a top medical journal.\n",
    "            Focus on the specific medical condition, treatment approach, and patient population mentioned.\"\"\"),\n",
    "            (\"human\", \"\"\"Generate a hypothetical research paper for this medical query:\n",
    "            \n",
    "            Query: {query}\n",
    "            Condition: {condition}\n",
    "            Treatment: {treatment_type}\n",
    "            Population: {patient_population}\n",
    "            \n",
    "            Create an ideal research paper that would perfectly answer this query.\"\"\")\n",
    "        ])\n",
    "        \n",
    "        # Step 3: Final Response Generation Prompt  \n",
    "        self.response_generation_prompt = ChatPromptTemplate.from_messages([\n",
    "            (\"system\", \"\"\"You are a medical research assistant providing evidence-based responses \n",
    "            to healthcare professionals. Use the retrieved medical literature to provide:\n",
    "            \n",
    "            1. A comprehensive answer to the original query\n",
    "            2. Current treatment approaches and their efficacy\n",
    "            3. Recent research developments\n",
    "            4. Clinical considerations and recommendations\n",
    "            5. Limitations and areas for future research\n",
    "            \n",
    "            Always cite relevant studies and maintain scientific accuracy.\n",
    "            Include appropriate medical disclaimers.\"\"\"),\n",
    "            (\"human\", \"\"\"Original Query: {query}\n",
    "            \n",
    "            Retrieved Medical Literature:\n",
    "            {documents}\n",
    "            \n",
    "            Provide a comprehensive, evidence-based response suitable for medical professionals.\"\"\")\n",
    "        ])\n",
    "    \n",
    "    def step1_analyze_query(self, state: HyDEMedicalState) -> HyDEMedicalState:\n",
    "        \"\"\"\n",
    "        STEP 1: QUERY ANALYSIS\n",
    "        Parse the medical query to understand the specific medical context.\n",
    "        This helps tailor the hypothetical document generation.\n",
    "        \"\"\"\n",
    "        print(\"\\nüîç STEP 1: Analyzing medical query...\")\n",
    "        \n",
    "        query = state[\"original_query\"]\n",
    "        \n",
    "        # Use structured output to parse the query\n",
    "        structured_llm = self.llm.with_structured_output(MedicalQuery)\n",
    "        \n",
    "        try:\n",
    "            parsed_query = structured_llm.invoke([\n",
    "                (\"system\", \"Analyze this medical query and extract key components.\"),\n",
    "                (\"human\", f\"Query: {query}\")\n",
    "            ])\n",
    "            \n",
    "            print(f\"   üìã Condition: {parsed_query.condition}\")\n",
    "            print(f\"   üíä Treatment: {parsed_query.treatment_type}\")\n",
    "            print(f\"   üë• Population: {parsed_query.patient_population}\")\n",
    "            print(f\"   ‚ö° Urgency: {parsed_query.urgency}\")\n",
    "            \n",
    "            state[\"parsed_query\"] = parsed_query\n",
    "            \n",
    "        except Exception as e:\n",
    "            print(f\"   ‚ö†Ô∏è Error in query analysis: {e}\")\n",
    "            # Fallback to basic parsing\n",
    "            state[\"parsed_query\"] = MedicalQuery(\n",
    "                condition=\"general\",\n",
    "                treatment_type=\"various\",\n",
    "                patient_population=\"general\",\n",
    "                urgency=\"routine\"\n",
    "            )\n",
    "        \n",
    "        return state\n",
    "    \n",
    "    def step2_generate_hypothetical_document(self, state: HyDEMedicalState) -> HyDEMedicalState:\n",
    "        \"\"\"\n",
    "        STEP 2: HYPOTHETICAL DOCUMENT GENERATION\n",
    "        This is the core of HyDE - generate what an ideal research paper would look like.\n",
    "        The hypothetical document serves as a semantic guide for retrieval.\n",
    "        \"\"\"\n",
    "        print(\"\\nüìù STEP 2: Generating hypothetical research paper...\")\n",
    "        \n",
    "        query = state[\"original_query\"]\n",
    "        parsed_query = state[\"parsed_query\"]\n",
    "        \n",
    "        # Generate hypothetical document\n",
    "        hypothetical_prompt_value = self.hypothetical_doc_prompt.invoke({\n",
    "            \"query\": query,\n",
    "            \"condition\": parsed_query.condition,\n",
    "            \"treatment_type\": parsed_query.treatment_type,\n",
    "            \"patient_population\": parsed_query.patient_population\n",
    "        })\n",
    "\n",
    "        hypothetical_response = self.llm.invoke(hypothetical_prompt_value)\n",
    "        print(hypothetical_response)\n",
    "        hypothetical_doc = hypothetical_response.content\n",
    "        \n",
    "        print(f\"   üìÑ Generated hypothetical paper ({len(hypothetical_doc)} characters)\")\n",
    "        print(f\"   üéØ Preview: {hypothetical_doc[:200]}...\")\n",
    "        \n",
    "        state[\"hypothetical_document\"] = hypothetical_doc\n",
    "        \n",
    "        return state\n",
    "    \n",
    "    def step3_embed_hypothetical_document(self, state: HyDEMedicalState) -> HyDEMedicalState:\n",
    "        \"\"\"\n",
    "        STEP 3: EMBED HYPOTHETICAL DOCUMENT\n",
    "        Convert the hypothetical document into embeddings that can be used for similarity search.\n",
    "        This is what makes HyDE different from traditional RAG.\n",
    "        \"\"\"\n",
    "        print(\"\\nüß† STEP 3: Creating embeddings for hypothetical document...\")\n",
    "        \n",
    "        hypothetical_doc = state[\"hypothetical_document\"]\n",
    "        \n",
    "        # Generate embeddings for the hypothetical document\n",
    "        embeddings = self.embeddings.embed_query(hypothetical_doc)\n",
    "        \n",
    "        print(f\"   üî¢ Generated {len(embeddings)} dimensional embedding vector\")\n",
    "        print(f\"   üìä Embedding sample: {embeddings[:5]}...\")\n",
    "        \n",
    "        state[\"search_embeddings\"] = embeddings\n",
    "        \n",
    "        return state\n",
    "    \n",
    "    def step4_retrieve_with_hypothetical_embeddings(self, state: HyDEMedicalState) -> HyDEMedicalState:\n",
    "        \"\"\"\n",
    "        STEP 4: RETRIEVE USING HYPOTHETICAL EMBEDDINGS\n",
    "        Use the hypothetical document embeddings to find similar real documents.\n",
    "        This often finds more relevant results than searching with the original query.\n",
    "        \"\"\"\n",
    "        print(\"\\nüîç STEP 4: Retrieving documents using hypothetical embeddings...\")\n",
    "        \n",
    "        retrieved_docs = []\n",
    "        \n",
    "        # Retrieve from medical knowledge base using hypothetical document\n",
    "        if self.medical_vectorstore:\n",
    "            try:\n",
    "                # Use the hypothetical document for retrieval instead of original query\n",
    "                docs = self.medical_vectorstore.invoke(state[\"hypothetical_document\"])\n",
    "                retrieved_docs.extend([{\"source\": \"knowledge_base\", \"content\": doc} for doc in docs])\n",
    "                print(f\"   üìö Retrieved {len(docs)} documents from medical knowledge base\")\n",
    "            except Exception as e:\n",
    "                print(f\"   ‚ö†Ô∏è Error retrieving from knowledge base: {e}\")\n",
    "        \n",
    "        # Also search for recent developments using web search\n",
    "        try:\n",
    "            # Use original query for web search to get current information\n",
    "            web_results = self.web_search.invoke({\"query\": f\"recent medical research {state['original_query']} 2024\"})\n",
    "            retrieved_docs.extend([{\"source\": \"web\", \"content\": result.get(\"content\", \"\")} for result in web_results])\n",
    "            print(f\"   üåê Retrieved {len(web_results)} recent research articles from web\")\n",
    "        except Exception as e:\n",
    "            print(f\"   ‚ö†Ô∏è Error in web search: {e}\")\n",
    "        \n",
    "        print(f\"   üìä Total retrieved documents: {len(retrieved_docs)}\")\n",
    "        \n",
    "        state[\"retrieved_documents\"] = retrieved_docs\n",
    "        \n",
    "        return state\n",
    "    \n",
    "    def step5_generate_final_response(self, state: HyDEMedicalState) -> HyDEMedicalState:\n",
    "        \"\"\"\n",
    "        STEP 5: GENERATE FINAL RESPONSE\n",
    "        Combine the retrieved documents with the original query to generate\n",
    "        a comprehensive medical research response.\n",
    "        \"\"\"\n",
    "        print(\"\\nüí¨ STEP 5: Generating final medical research response...\")\n",
    "        \n",
    "        query = state[\"original_query\"]\n",
    "        documents = state[\"retrieved_documents\"]\n",
    "        \n",
    "        # Format documents for the prompt\n",
    "        formatted_docs = []\n",
    "        for i, doc in enumerate(documents, 1):\n",
    "            source = doc.get(\"source\", \"unknown\")\n",
    "            content = doc.get(\"content\", \"\")\n",
    "            formatted_docs.append(f\"Document {i} ({source}):\\n{content}\\n\")\n",
    "        \n",
    "        documents_text = \"\\n\".join(formatted_docs)\n",
    "        \n",
    "        # Generate comprehensive response\n",
    "        response_prompt_value = self.response_generation_prompt.invoke({\n",
    "            \"query\": query,\n",
    "            \"documents\": documents_text\n",
    "        })\n",
    "        response = self.llm.invoke(response_prompt_value)\n",
    "        \n",
    "        final_response = response.content\n",
    "        \n",
    "        print(f\"   ‚úÖ Generated comprehensive response ({len(final_response)} characters)\")\n",
    "        \n",
    "        state[\"final_response\"] = final_response\n",
    "        \n",
    "        return state\n",
    "    \n",
    "    def run_hyde_workflow(self, medical_query: str) -> Dict[str, Any]:\n",
    "        \"\"\"\n",
    "        Execute the complete HyDE workflow for medical research.\n",
    "        \n",
    "        Args:\n",
    "            medical_query: The medical research question\n",
    "            \n",
    "        Returns:\n",
    "            Complete workflow results including hypothetical document and final response\n",
    "        \"\"\"\n",
    "        print(f\"\\nüè• STARTING HyDE MEDICAL RESEARCH WORKFLOW\")\n",
    "        print(f\"Query: {medical_query}\")\n",
    "        print(\"=\" * 80)\n",
    "        \n",
    "        # Initialize state\n",
    "        state = HyDEMedicalState(\n",
    "            original_query=medical_query,\n",
    "            parsed_query=None,\n",
    "            hypothetical_document=\"\",\n",
    "            retrieved_documents=[],\n",
    "            final_response=\"\",\n",
    "            search_embeddings=[]\n",
    "        )\n",
    "        \n",
    "        # Execute workflow steps\n",
    "        state = self.step1_analyze_query(state)\n",
    "        state = self.step2_generate_hypothetical_document(state)\n",
    "        state = self.step3_embed_hypothetical_document(state)\n",
    "        state = self.step4_retrieve_with_hypothetical_embeddings(state)\n",
    "        state = self.step5_generate_final_response(state)\n",
    "        \n",
    "        print(\"\\n‚úÖ HyDE WORKFLOW COMPLETED\")\n",
    "        print(\"=\" * 80)\n",
    "        \n",
    "        return state\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 16,
   "id": "2482165f",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "üè• HyDE RAG: Medical Research Assistant\n",
      "==================================================\n",
      "This system demonstrates Hypothetical Document Embedding (HyDE)\n",
      "for medical research queries. HyDE improves retrieval by first\n",
      "generating hypothetical ideal research papers, then using them\n",
      "to guide document retrieval.\n",
      "\n",
      "üìö Building medical knowledge base...\n",
      "\n",
      "#################### EXAMPLE 1 ####################\n",
      "Description: Complex pediatric oncology query requiring recent research\n",
      "Query: What are the latest immunotherapy approaches for treating pediatric acute lymphoblastic leukemia with resistance to conventional chemotherapy?\n",
      "\n",
      "üè• STARTING HyDE MEDICAL RESEARCH WORKFLOW\n",
      "Query: What are the latest immunotherapy approaches for treating pediatric acute lymphoblastic leukemia with resistance to conventional chemotherapy?\n",
      "================================================================================\n",
      "\n",
      "üîç STEP 1: Analyzing medical query...\n",
      "   üìã Condition: pediatric acute lymphoblastic leukemia\n",
      "   üíä Treatment: immunotherapy\n",
      "   üë• Population: children\n",
      "   ‚ö° Urgency: urgent\n",
      "\n",
      "üìù STEP 2: Generating hypothetical research paper...\n",
      "content='## Novel Chimeric Antigen Receptor T-Cell Therapy Targeting CD19 for Relapsed/Refractory Pediatric Acute Lymphoblastic Leukemia\\n\\n**Abstract**\\n\\n**Background:** Pediatric acute lymphoblastic leukemia (ALL) is the most common childhood malignancy, with conventional chemotherapy achieving high cure rates in most cases. However, a significant proportion of children experience relapse or refractory disease, leading to poor prognoses. Immunotherapy offers a promising alternative or adjunct to conventional chemotherapy for these high-risk patients. \\n\\n**Methods:** This phase II clinical trial evaluated the safety and efficacy of CD19-targeted chimeric antigen receptor (CAR) T-cell therapy in children (aged 1-18 years) with relapsed/refractory ALL who had received at least two prior chemotherapy regimens. Patients underwent lymphodepleting chemotherapy followed by infusion of autologous T-cells genetically engineered to express a second-generation anti-CD19 CAR. The primary endpoint was complete remission (CR) rate at 3 months post-infusion. Secondary endpoints included overall survival (OS), duration of remission, and safety profile.\\n\\n**Results:** Twenty-four patients were enrolled in the trial. The median age was 8 years, and 63% were male. The most common cytogenetic risk group was high-risk (54%).  The overall CR rate at 3 months was 67% (16/24), with 8% achieving a CR with minimal residual disease (MRD). The median OS was 18 months, with a 1-year survival rate of 58%.  Cytokine release syndrome (CRS) was observed in 83% of patients, with 17% experiencing grade 3 or 4 CRS. Neurotoxicity was observed in 33% of patients, with 4% experiencing grade 3 or 4 neurotoxicity.\\n\\n**Conclusions:** CD19-targeted CAR T-cell therapy demonstrates promising efficacy and a manageable safety profile in children with relapsed/refractory ALL. Notably, the high CR rate and improved OS compared to historical data with salvage therapies suggest its potential as a valuable treatment option for this vulnerable patient population. Further research with larger cohorts and long-term follow-up is warranted to optimize treatment protocols and refine patient selection criteria.\\n\\n\\n**Key Findings:**\\n\\n* **High CR rate:** 67% of patients achieved complete remission after CD19 CAR T-cell therapy, suggesting a significant response rate.\\n* **Improved OS:**  The median OS of 18 months represents a substantial improvement compared to historical survival rates for patients with relapsed/refractory ALL who have exhausted conventional therapy.\\n* **Safety profile:** While CRS and neurotoxicity were observed, the majority of events were manageable with supportive care.\\n\\n\\n\\nThis hypothetical research paper highlights the potential of CD19 CAR T-cell therapy for children with relapsed/refractory ALL. It emphasizes the high CR rate and improved OS compared to standard treatment options, while acknowledging the need for further research to optimize treatment strategies and minimize potential side effects. \\n' additional_kwargs={} response_metadata={'token_usage': {'completion_tokens': 639, 'prompt_tokens': 198, 'total_tokens': 837, 'completion_time': 1.161818182, 'prompt_time': 0.009076775, 'queue_time': 0.259507823, 'total_time': 1.170894957}, 'model_name': 'Gemma2-9b-It', 'system_fingerprint': 'fp_10c08bf97d', 'finish_reason': 'stop', 'logprobs': None} id='run--c8efb82b-d88d-4d56-821d-043613c16de2-0' usage_metadata={'input_tokens': 198, 'output_tokens': 639, 'total_tokens': 837}\n",
      "   üìÑ Generated hypothetical paper (3004 characters)\n",
      "   üéØ Preview: ## Novel Chimeric Antigen Receptor T-Cell Therapy Targeting CD19 for Relapsed/Refractory Pediatric Acute Lymphoblastic Leukemia\n",
      "\n",
      "**Abstract**\n",
      "\n",
      "**Background:** Pediatric acute lymphoblastic leukemia (A...\n",
      "\n",
      "üß† STEP 3: Creating embeddings for hypothetical document...\n",
      "   üî¢ Generated 768 dimensional embedding vector\n",
      "   üìä Embedding sample: [0.023500753566622734, -0.047529399394989014, -0.06793947517871857, 0.050368424504995346, 0.05889806151390076]...\n",
      "\n",
      "üîç STEP 4: Retrieving documents using hypothetical embeddings...\n",
      "   üìö Retrieved 3 documents from medical knowledge base\n",
      "   ‚ö†Ô∏è Error in web search: 'str' object has no attribute 'get'\n",
      "   üìä Total retrieved documents: 3\n",
      "\n",
      "üí¨ STEP 5: Generating final medical research response...\n",
      "   ‚úÖ Generated comprehensive response (4026 characters)\n",
      "\n",
      "‚úÖ HyDE WORKFLOW COMPLETED\n",
      "================================================================================\n",
      "\n",
      "üìã WORKFLOW SUMMARY:\n",
      "   Original Query: What are the latest immunotherapy approaches for treating pediatric acute lymphoblastic leukemia with resistance to conventional chemotherapy?\n",
      "   Parsed Condition: pediatric acute lymphoblastic leukemia\n",
      "   Treatment Type: immunotherapy\n",
      "   Documents Retrieved: 3\n",
      "\n",
      "üìù HYPOTHETICAL DOCUMENT PREVIEW:\n",
      "## Novel Chimeric Antigen Receptor T-Cell Therapy Targeting CD19 for Relapsed/Refractory Pediatric Acute Lymphoblastic Leukemia\n",
      "\n",
      "**Abstract**\n",
      "\n",
      "**Background:** Pediatric acute lymphoblastic leukemia (ALL) is the most common childhood malignancy, with conventional chemotherapy achieving high cure rates in most cases. However, a significant proportion of children experience relapse or refractory disease, leading to poor prognoses. Immunotherapy offers a promising alternative or adjunct to conventio...\n",
      "\n",
      "üéØ FINAL RESPONSE:\n",
      "## Immunotherapy Approaches for Pediatric ALL with Chemotherapy Resistance\n",
      "\n",
      "The management of pediatric acute lymphoblastic leukemia (ALL) with resistance to conventional chemotherapy remains a significant challenge. Fortunately, recent advancements in immunotherapy offer promising new treatment options.\n",
      "\n",
      "**1. CAR-T Cell Therapy:**\n",
      "\n",
      "Chimeric Antigen Receptor T-cell (CAR-T) therapy has demonstrated remarkable efficacy in treating relapsed/refractory B-cell ALL. \n",
      "\n",
      "* **Evidence:** A study by Smith et al. (Journal of Pediatric Oncology, 2024) reported complete remission rates of 89% in this patient population treated with tisagenlecleucel.  \n",
      "* **Mechanism:** CAR-T cells are genetically engineered to express a specific receptor that targets antigens on leukemia cells, enabling them to recognize and destroy the malignant cells.\n",
      "\n",
      "**2. Bispecific T-cell Engagers (BiTEs):**\n",
      "\n",
      "BiTEs, such as blinatumomab, bridge T-cells and leukemia cells, triggering T-cell-mediated cytotoxicity.\n",
      "\n",
      "* **Evidence:** Johnson et al. (Blood Cancer Research, 2024) conducted a multicenter study involving 78 pediatric patients with relapsed/refractory B-ALL treated with blinatumomab. Results showed an overall response rate of 73% with a manageable toxicity profile.\n",
      "* **Clinical Considerations:** Cytokine release syndrome (CRS) was observed in 23% of patients, highlighting the need for careful monitoring and management.\n",
      "\n",
      "**3. Checkpoint Inhibitors:**\n",
      "\n",
      "Checkpoint inhibitors are designed to release the \"brakes\" on the immune system, allowing T-cells to more effectively target cancer cells.\n",
      "\n",
      "* **Evidence:**  Chen et al. (Pediatric Hematology Today, 2024) reviewed emerging immunotherapy strategies in pediatric hematological malignancies, highlighting the promising results of combination immunotherapy approaches, including checkpoint inhibitors, in preclinical and early clinical trials.\n",
      "\n",
      "**4. Combination Immunotherapy:**\n",
      "\n",
      "Combining different immunotherapies, such as CAR-T cell therapy with checkpoint inhibitors, is an area of active research.\n",
      "\n",
      "* **Rationale:** This approach aims to overcome resistance mechanisms and enhance the anti-tumor immune response.\n",
      "* **Evidence:** Chen et al. (2024) emphasized the potential of combination immunotherapy strategies, noting enhanced efficacy with acceptable toxicity profiles observed in preclinical and early clinical trials.\n",
      "\n",
      "**5. Recent Research Developments:**\n",
      "\n",
      "* **Novel Antigen Targets:** Research is ongoing to identify new and more specific antigen targets for CAR-T cell therapy, aiming to improve efficacy and minimize off-target effects.\n",
      "* **Enhanced Safety Profiles:** Strategies to mitigate the risks of CRS and other immune-related adverse events are being explored.\n",
      "* **Personalized Approaches:**  Efforts are underway to tailor immunotherapy approaches to individual patients based on their genetic and molecular profiles.\n",
      "\n",
      "**Clinical Considerations and Recommendations:**\n",
      "\n",
      "* **Patient Selection:** Careful patient selection is crucial for immunotherapy, considering factors such as disease status, age, and overall health.\n",
      "* **Close Monitoring:**  Patients receiving immunotherapy require close monitoring for both efficacy and potential adverse events.\n",
      "* **Multidisciplinary Care:** Management of pediatric ALL with immunotherapy requires a multidisciplinary team approach involving oncologists, immunologists, nurses, and other healthcare professionals.\n",
      "\n",
      "**Limitations and Areas for Future Research:**\n",
      "\n",
      "* **Long-Term Outcomes:**  Long-term follow-up data on the effectiveness and safety of immunotherapy in pediatric ALL are still limited.\n",
      "* **Resistance Mechanisms:** Understanding and overcoming resistance mechanisms to immunotherapy remains a key challenge.\n",
      "* **Cost and Accessibility:**  The cost of immunotherapy can be a barrier to access for some patients.\n",
      "\n",
      "**Disclaimer:**  This information is for educational purposes only and should not be considered medical advice. Please consult with a qualified healthcare professional for diagnosis and treatment of ALL.\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "##################################################\n",
      "\n",
      "#################### EXAMPLE 2 ####################\n",
      "Description: Comparative effectiveness research question\n",
      "Query: How effective is CAR-T cell therapy compared to traditional chemotherapy for relapsed B-cell lymphomas in elderly patients?\n",
      "\n",
      "üè• STARTING HyDE MEDICAL RESEARCH WORKFLOW\n",
      "Query: How effective is CAR-T cell therapy compared to traditional chemotherapy for relapsed B-cell lymphomas in elderly patients?\n",
      "================================================================================\n",
      "\n",
      "üîç STEP 1: Analyzing medical query...\n",
      "   üìã Condition: relapsed B-cell lymphomas\n",
      "   üíä Treatment: CAR-T cell therapy\n",
      "   üë• Population: elderly patients\n",
      "   ‚ö° Urgency: routine\n",
      "\n",
      "üìù STEP 2: Generating hypothetical research paper...\n",
      "content='##  Chimeric Antigen Receptor T-Cell Therapy vs. Chemotherapy in Elderly Patients with Relapsed B-Cell Lymphoma: A Two-Armed Randomized Controlled Trial\\n\\n**Abstract**\\n\\n**Background:** Relapsed B-cell lymphoma (B-NHL) in elderly patients often carries a poor prognosis, with limited effective treatment options. Chimeric antigen receptor T-cell (CAR-T) therapy has shown remarkable efficacy in younger patients, but its application in the elderly remains controversial due to age-related comorbidities and potential safety concerns. This study aimed to compare the efficacy and safety of CAR-T cell therapy with conventional chemotherapy in elderly patients with relapsed B-NHL.\\n\\n**Methods:** This randomized controlled trial enrolled 120 patients aged 65 years and older with relapsed B-NHL who had received at least two prior systemic therapies. Patients were randomly assigned 1:1 to receive either CAR-T cell therapy targeting CD19 or standard chemotherapy (CHOP-like regimen). The primary endpoint was progression-free survival (PFS) at 12 months, while secondary endpoints included overall survival (OS), complete response rate (CR), and incidence of adverse events.\\n\\n**Results:**  Patients in the CAR-T cell therapy group (n=60) had a significantly longer median PFS at 12 months compared to the chemotherapy group (n=60) (11.2 months vs. 4.8 months, p<0.001).  The CAR-T cell therapy group also demonstrated a higher CR rate (45% vs. 18%, p<0.001) and improved OS (median OS not reached vs. 16.4 months, p=0.002).  While both treatment arms experienced adverse events, the incidence of Grade 3 or higher toxicity was higher in the CAR-T cell therapy group (55% vs. 25%, p=0.008), primarily consisting of cytokine release syndrome (CRS) and neurotoxicity. Notably, all severe CRS events were manageable with supportive care.\\n\\n**Conclusions:** CAR-T cell therapy demonstrates superior efficacy compared to conventional chemotherapy in elderly patients with relapsed B-NHL, significantly improving PFS, CR rates, and OS. Despite a higher incidence of adverse events, most were manageable with current supportive care strategies. This study suggests CAR-T cell therapy as a promising treatment option for elderly patients with relapsed B-NHL.\\n\\n**Key Findings:**\\n\\n* **Superiority of CAR-T:** CAR-T cell therapy significantly outperformed conventional chemotherapy in terms of progression-free survival (PFS), complete response rates (CR), and overall survival (OS) in elderly patients with relapsed B-NHL. \\n* **Safety Profile:** While CAR-T cell therapy was associated with a higher incidence of Grade 3 or higher toxicity (primarily CRS and neurotoxicity), these events were manageable with supportive care.\\n* **Age-Specific Benefits:** This study highlights the potential of CAR-T cell therapy to benefit a population often excluded from clinical trials due to age-related concerns.\\n\\n\\n\\n' additional_kwargs={} response_metadata={'token_usage': {'completion_tokens': 646, 'prompt_tokens': 208, 'total_tokens': 854, 'completion_time': 1.174545455, 'prompt_time': 0.008385755, 'queue_time': 0.259387784, 'total_time': 1.18293121}, 'model_name': 'Gemma2-9b-It', 'system_fingerprint': 'fp_10c08bf97d', 'finish_reason': 'stop', 'logprobs': None} id='run--e61ea0d3-9ed4-4cda-b733-fb42c7c506ea-0' usage_metadata={'input_tokens': 208, 'output_tokens': 646, 'total_tokens': 854}\n",
      "   üìÑ Generated hypothetical paper (2890 characters)\n",
      "   üéØ Preview: ##  Chimeric Antigen Receptor T-Cell Therapy vs. Chemotherapy in Elderly Patients with Relapsed B-Cell Lymphoma: A Two-Armed Randomized Controlled Trial\n",
      "\n",
      "**Abstract**\n",
      "\n",
      "**Background:** Relapsed B-cell ...\n",
      "\n",
      "üß† STEP 3: Creating embeddings for hypothetical document...\n",
      "   üî¢ Generated 768 dimensional embedding vector\n",
      "   üìä Embedding sample: [0.029104085639119148, -0.029968418180942535, -0.0691998302936554, -0.0036687012761831284, 0.06886295974254608]...\n",
      "\n",
      "üîç STEP 4: Retrieving documents using hypothetical embeddings...\n",
      "   üìö Retrieved 3 documents from medical knowledge base\n",
      "   ‚ö†Ô∏è Error in web search: 'str' object has no attribute 'get'\n",
      "   üìä Total retrieved documents: 3\n",
      "\n",
      "üí¨ STEP 5: Generating final medical research response...\n",
      "   ‚úÖ Generated comprehensive response (3622 characters)\n",
      "\n",
      "‚úÖ HyDE WORKFLOW COMPLETED\n",
      "================================================================================\n",
      "\n",
      "üìã WORKFLOW SUMMARY:\n",
      "   Original Query: How effective is CAR-T cell therapy compared to traditional chemotherapy for relapsed B-cell lymphomas in elderly patients?\n",
      "   Parsed Condition: relapsed B-cell lymphomas\n",
      "   Treatment Type: CAR-T cell therapy\n",
      "   Documents Retrieved: 3\n",
      "\n",
      "üìù HYPOTHETICAL DOCUMENT PREVIEW:\n",
      "##  Chimeric Antigen Receptor T-Cell Therapy vs. Chemotherapy in Elderly Patients with Relapsed B-Cell Lymphoma: A Two-Armed Randomized Controlled Trial\n",
      "\n",
      "**Abstract**\n",
      "\n",
      "**Background:** Relapsed B-cell lymphoma (B-NHL) in elderly patients often carries a poor prognosis, with limited effective treatment options. Chimeric antigen receptor T-cell (CAR-T) therapy has shown remarkable efficacy in younger patients, but its application in the elderly remains controversial due to age-related comorbidities...\n",
      "\n",
      "üéØ FINAL RESPONSE:\n",
      "## CAR-T Cell Therapy vs. Traditional Chemotherapy for Relapsed B-cell Lymphoma in Elderly Patients: A Review \n",
      "\n",
      "**Original Query:** How effective is CAR-T cell therapy compared to traditional chemotherapy for relapsed B-cell lymphomas in elderly patients?\n",
      "\n",
      "**Response:**  While the provided medical literature focuses primarily on pediatric hematological malignancies, it offers valuable insights into the evolving landscape of immunotherapy, particularly CAR-T cell therapy. \n",
      "\n",
      "Unfortunately, direct comparisons between CAR-T cell therapy and traditional chemotherapy for relapsed B-cell lymphomas in elderly patients are not addressed in these documents.  \n",
      "\n",
      "However, we can glean some information and extrapolate potential considerations:\n",
      "\n",
      "**1. CAR-T Cell Therapy Efficacy:**\n",
      "\n",
      "* Document 1 highlights the remarkable success of CAR-T therapy in treating pediatric B-cell ALL, achieving 89% complete remission rates in relapsed/refractory cases. This suggests its potential efficacy against B-cell malignancies.\n",
      "* Document 2 demonstrates the efficacy of blinatumomab (a BiTE therapy) in pediatric patients with chemotherapy-resistant B-ALL, with an overall response rate of 73%. This further emphasizes the potential of immunotherapy in this patient population.\n",
      "\n",
      "**2. Treatment Approaches and Efficacy:**\n",
      "\n",
      "* **Traditional Chemotherapy:** For elderly patients with relapsed B-cell lymphomas, traditional chemotherapy often remains a primary treatment option. However, efficacy can vary depending on the specific type of lymphoma, patient fitness, and prior treatment history.\n",
      "* **CAR-T Cell Therapy:** While promising, CAR-T cell therapy is still considered an experimental treatment for many elderly patients due to potential risks and limited long-term data.\n",
      "\n",
      "**3. Recent Research Developments:**\n",
      "\n",
      "* Document 3 emphasizes the growing field of immunotherapy in pediatric hematological malignancies, including checkpoint inhibitors and combination therapies. These advancements could potentially translate to improved treatment strategies for elderly patients in the future.\n",
      "\n",
      "**4. Clinical Considerations and Recommendations:**\n",
      "\n",
      "* **Patient Selection:** Elderly patients with relapsed B-cell lymphomas require careful evaluation to determine their suitability for CAR-T cell therapy. Factors like overall health, comorbidities, and prior treatment history should be considered.\n",
      "* **Risk-Benefit Analysis:** A thorough discussion of potential benefits and risks associated with both CAR-T cell therapy and traditional chemotherapy is crucial for shared decision-making with patients.\n",
      "* **Clinical Trial Participation:** Encouraging eligible patients to participate in clinical trials investigating CAR-T cell therapy and other novel immunotherapies is essential for advancing treatment options.\n",
      "\n",
      "**5. Limitations and Areas for Future Research:**\n",
      "\n",
      "* **Limited Data on Elderly Patients:** The current literature lacks sufficient data on the efficacy and safety of CAR-T cell therapy in elderly patients with relapsed B-cell lymphomas.\n",
      "* **Long-Term Outcomes:** Long-term follow-up data are needed to fully understand the durability of responses and potential late-onset complications associated with CAR-T cell therapy in elderly populations.\n",
      "* **Personalized Approaches:** Research is needed to identify predictive biomarkers that can help personalize CAR-T cell therapy and optimize treatment outcomes for individual patients.\n",
      "\n",
      "\n",
      "**Disclaimer:** This information is for educational purposes only and should not be considered medical advice. Consult with a qualified healthcare professional for personalized medical guidance. \n",
      "\n",
      "\n",
      "##################################################\n",
      "\n",
      "#################### EXAMPLE 3 ####################\n",
      "Description: Current research and clinical trials query\n",
      "Query: What are the current clinical trials investigating combination immunotherapy for triple-negative breast cancer?\n",
      "\n",
      "üè• STARTING HyDE MEDICAL RESEARCH WORKFLOW\n",
      "Query: What are the current clinical trials investigating combination immunotherapy for triple-negative breast cancer?\n",
      "================================================================================\n",
      "\n",
      "üîç STEP 1: Analyzing medical query...\n",
      "   üìã Condition: triple-negative breast cancer\n",
      "   üíä Treatment: immunotherapy\n",
      "   üë• Population: all\n",
      "   ‚ö° Urgency: routine\n",
      "\n",
      "üìù STEP 2: Generating hypothetical research paper...\n",
      "content='##  Expanding the Frontiers: A Review of Ongoing Clinical Trials Investigating Combination Immunotherapy for Triple-Negative Breast Cancer\\n\\n**Abstract**\\n\\nTriple-negative breast cancer (TNBC), characterized by the absence of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) expression, remains a challenging subtype with limited therapeutic options. Immunotherapy has emerged as a promising approach, demonstrating clinical efficacy in certain TNBC patients.  This review analyzes ongoing clinical trials investigating the efficacy and safety of combination immunotherapy regimens in TNBC. We systematically searched clinical trial databases (ClinicalTrials.gov, EU Clinical Trials Register) for trials enrolling patients with TNBC and utilizing immunotherapies, including immune checkpoint inhibitors (ICIs), adoptive cell transfer, and oncolytic viruses. Inclusion criteria encompassed all stages of TNBC and diverse treatment combinations.  Analysis of 53 ongoing trials revealed a shift towards multi-pronged immunotherapeutic approaches. Key findings highlight the investigation of ICIs in combination with chemotherapy, targeted therapies, and other immunotherapies. Notably, trials exploring the synergistic potential of  PD-1/PD-L1 inhibitors with anti-CTLA-4 antibodies and T-cell receptor (TCR)-engineered T-cell therapy are gaining traction.  These findings suggest a promising future for combination immunotherapy in improving outcomes for TNBC patients.\\n\\n**Key Findings**\\n\\n* **Prevalence of Combination Regimens:** A significant proportion (70%) of the analyzed trials investigated combination immunotherapies, underscoring the growing focus on synergistic approaches.\\n* **Dominance of ICIs:** Immune checkpoint inhibitors, particularly PD-1/PD-L1 inhibitors, constitute the cornerstone of most combination regimens, appearing in 85% of the trials.\\n* **Expanding Partnerships:**  Trials demonstrate a move beyond single ICIs, with a notable increase in the investigation of PD-1/PD-L1 inhibitors paired with anti-CTLA-4 antibodies (25% of trials). This combination aims to activate both effector and memory T-cell responses.\\n* **Cellular Immunotherapy Surge:**  A notable 15% of trials explore the use of adoptive cell therapy, including TCR-engineered T-cells,  targeting tumor-specific antigens in TNBC.\\n* **Early-Stage Trials Dominate:**  The majority of ongoing trials are in early-phase (I/II) settings, reflecting the need for further investigation into optimal dosing, safety profiles, and efficacy of these novel combinations.\\n\\n**Discussion**\\n\\nThe current landscape of TNBC treatment is undergoing a paradigm shift with the advent of immunotherapy. \\n\\nThese findings highlight the ongoing efforts to optimize immunotherapeutic approaches by combining ICIs with other agents like chemotherapy, targeted therapies, and cellular immunotherapies. \\n\\nWhile early-stage trials are currently underway, the results hold immense potential for improving patient outcomes in TNBC.  Further research is crucial to determine the long-term efficacy and safety of these combination regimens and to identify predictive biomarkers for patient selection, ultimately paving the way for personalized immunotherapies for TNBC. \\n\\n\\n**Note:** This research paper is hypothetical and does not represent actual ongoing clinical trials. \\n\\n\\n' additional_kwargs={} response_metadata={'token_usage': {'completion_tokens': 662, 'prompt_tokens': 193, 'total_tokens': 855, 'completion_time': 1.203636364, 'prompt_time': 0.009470815, 'queue_time': 1.413669983, 'total_time': 1.213107179}, 'model_name': 'Gemma2-9b-It', 'system_fingerprint': 'fp_10c08bf97d', 'finish_reason': 'stop', 'logprobs': None} id='run--5ef67a55-023a-488a-bb9e-8a30a3e627f0-0' usage_metadata={'input_tokens': 193, 'output_tokens': 662, 'total_tokens': 855}\n",
      "   üìÑ Generated hypothetical paper (3386 characters)\n",
      "   üéØ Preview: ##  Expanding the Frontiers: A Review of Ongoing Clinical Trials Investigating Combination Immunotherapy for Triple-Negative Breast Cancer\n",
      "\n",
      "**Abstract**\n",
      "\n",
      "Triple-negative breast cancer (TNBC), characte...\n",
      "\n",
      "üß† STEP 3: Creating embeddings for hypothetical document...\n",
      "   üî¢ Generated 768 dimensional embedding vector\n",
      "   üìä Embedding sample: [0.03871425241231918, -0.04773040488362312, -0.034307073801755905, 0.034495092928409576, 0.0364641509950161]...\n",
      "\n",
      "üîç STEP 4: Retrieving documents using hypothetical embeddings...\n",
      "   üìö Retrieved 3 documents from medical knowledge base\n",
      "   ‚ö†Ô∏è Error in web search: 'str' object has no attribute 'get'\n",
      "   üìä Total retrieved documents: 3\n",
      "\n",
      "üí¨ STEP 5: Generating final medical research response...\n",
      "   ‚úÖ Generated comprehensive response (3876 characters)\n",
      "\n",
      "‚úÖ HyDE WORKFLOW COMPLETED\n",
      "================================================================================\n",
      "\n",
      "üìã WORKFLOW SUMMARY:\n",
      "   Original Query: What are the current clinical trials investigating combination immunotherapy for triple-negative breast cancer?\n",
      "   Parsed Condition: triple-negative breast cancer\n",
      "   Treatment Type: immunotherapy\n",
      "   Documents Retrieved: 3\n",
      "\n",
      "üìù HYPOTHETICAL DOCUMENT PREVIEW:\n",
      "##  Expanding the Frontiers: A Review of Ongoing Clinical Trials Investigating Combination Immunotherapy for Triple-Negative Breast Cancer\n",
      "\n",
      "**Abstract**\n",
      "\n",
      "Triple-negative breast cancer (TNBC), characterized by the absence of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) expression, remains a challenging subtype with limited therapeutic options. Immunotherapy has emerged as a promising approach, demonstrating clinical efficacy in certain TN...\n",
      "\n",
      "üéØ FINAL RESPONSE:\n",
      "## Current Clinical Trials Investigating Combination Immunotherapy for Triple-Negative Breast Cancer\n",
      "\n",
      "While the provided medical literature focuses on pediatric hematological malignancies, it highlights the growing field of immunotherapy and its promising results. Unfortunately, the documents do not contain information specifically about clinical trials investigating combination immunotherapy for triple-negative breast cancer (TNBC). \n",
      "\n",
      "To answer your query accurately, I recommend consulting clinical trial registries such as:\n",
      "\n",
      "* **ClinicalTrials.gov:** [https://clinicaltrials.gov/](https://clinicaltrials.gov/) - This is a comprehensive resource maintained by the U.S. National Institutes of Health (NIH).\n",
      "* **EU Clinical Trials Register:** [https://www.clinicaltrialsregister.eu/](https://www.clinicaltrialsregister.eu/) - A European Union-based registry.\n",
      "* **WHO International Clinical Trials Registry Platform (ICTRP):** [https://www.who.int/ictrp/](https://www.who.int/ictrp/) - A global platform for trial registration.\n",
      "\n",
      "**General Information on Immunotherapy for TNBC:**\n",
      "\n",
      "Although specific trials for TNBC combination immunotherapy are not detailed in the provided documents, immunotherapy is a rapidly evolving area in TNBC treatment. \n",
      "\n",
      "* **Immune checkpoint inhibitors (ICIs):**  ICIs like pembrolizumab and atezolizumab have shown some efficacy in treating TNBC, particularly in patients with high PD-L1 expression. \n",
      "* **CAR T-cell therapy:** While primarily used in hematologic malignancies, research is exploring its potential for solid tumors like TNBC. \n",
      "* **Combination strategies:** Clinical trials are actively investigating combining ICIs with other therapies like chemotherapy, targeted therapies, or radiotherapy to improve outcomes.\n",
      "\n",
      "**Current Treatment Approaches and Efficacy:**\n",
      "\n",
      "Treatment for TNBC depends on various factors, including tumor stage, grade, and patient characteristics. \n",
      "\n",
      "* **Neoadjuvant chemotherapy:** This involves chemotherapy before surgery to shrink the tumor.\n",
      "* **Surgery:** Removal of the tumor and surrounding tissue.\n",
      "* **Adjuvant chemotherapy:** Chemotherapy after surgery to reduce the risk of recurrence.\n",
      "* **Radiation therapy:** \n",
      "Targeting the tumor area after surgery.\n",
      "* **Targeted therapies:** Drugs that target specific proteins involved in tumor growth.\n",
      "\n",
      "**Recent Research Developments:**\n",
      "\n",
      "* Ongoing clinical trials are exploring novel combination immunotherapy approaches for TNBC.\n",
      "* Research is focusing on identifying biomarkers to predict which patients will benefit most from immunotherapy.\n",
      "* Scientists are investigating strategies to overcome resistance to immunotherapy.\n",
      "\n",
      "**Clinical Considerations and Recommendations:**\n",
      "\n",
      "Healthcare professionals should consider the following when evaluating immunotherapy for TNBC:\n",
      "\n",
      "* **Patient eligibility:** Ensure patients meet the criteria for specific clinical trials.\n",
      "* **Potential benefits and risks:** Discuss the potential benefits and risks of immunotherapy with patients.\n",
      "* **Monitoring for side effects:** Closely monitor patients for immunotherapy-related side effects.\n",
      "* **Personalized treatment:** Tailor treatment plans based on individual patient characteristics and tumor profile.\n",
      "\n",
      "**Limitations and Areas for Future Research:**\n",
      "\n",
      "* Limited data on long-term efficacy and safety of combination immunotherapy for TNBC.\n",
      "* Need for further research to identify biomarkers that predict response to immunotherapy.\n",
      "* Understanding and overcoming resistance mechanisms to immunotherapy.\n",
      "\n",
      "\n",
      "**Disclaimer:** I am an AI chatbot and cannot provide medical advice. This information is for general knowledge purposes only and should not be considered a substitute for professional medical advice, diagnosis, or treatment. Always consult with a qualified healthcare professional for any health concerns or before making any decisions related to your health or treatment.\n",
      "\n",
      "\n",
      "##################################################\n",
      "\n",
      "üî¨ COMPARISON: HyDE vs Traditional RAG\n",
      "============================================================\n",
      "üìö Building medical knowledge base...\n",
      "Query: What are breakthrough immunotherapy treatments for chemotherapy-resistant pediatric leukemia?\n",
      "\n",
      "üîç TRADITIONAL RAG APPROACH:\n",
      "   - Searches directly with user query\n",
      "   - May miss relevant papers due to vocabulary mismatch\n",
      "   - Limited by exact keyword matching\n",
      "   - Retrieved 3 documents\n",
      "   - Sample result: page_content='Title: Novel Immunotherapeutic Approaches for Pediatric Hematological Malignancies\n",
      "Content: \n",
      "                Abstract: The landscape of pediatric hematological malignancy treatment has e...\n",
      "\n",
      "üß† HyDE RAG APPROACH:\n",
      "   - First generates hypothetical ideal research paper\n",
      "   - Uses rich medical terminology and context\n",
      "   - Retrieves based on semantic similarity to ideal answer\n",
      "\n",
      "üè• STARTING HyDE MEDICAL RESEARCH WORKFLOW\n",
      "Query: What are breakthrough immunotherapy treatments for chemotherapy-resistant pediatric leukemia?\n",
      "================================================================================\n",
      "\n",
      "üîç STEP 1: Analyzing medical query...\n",
      "   üìã Condition: chemotherapy-resistant pediatric leukemia\n",
      "   üíä Treatment: immunotherapy\n",
      "   üë• Population: pediatric\n",
      "   ‚ö° Urgency: critical\n",
      "\n",
      "üìù STEP 2: Generating hypothetical research paper...\n",
      "content=\"## CAR T-Cell Therapy with a Novel CD19/CD22 Bispecific Construct Demonstrates Durable Remissions in Chemotherapy-Resistant Pediatric B-Cell Acute Lymphoblastic Leukemia\\n\\n**Abstract**\\n\\n**Background:** Chemotherapy-resistant pediatric B-cell acute lymphoblastic leukemia (B-ALL) remains a significant clinical challenge with limited treatment options. Chimeric antigen receptor (CAR) T-cell therapy has emerged as a promising treatment modality, targeting specific leukemia-associated antigens. However, antigen escape and relapse remain major hurdles.\\n\\n**Methods:** We conducted a single-arm, phase II clinical trial evaluating the safety and efficacy of a novel second-generation CAR T-cell therapy targeting both CD19 and CD22 (BiCAR) in children with relapsed/refractory B-ALL who were ineligible for or had failed conventional chemotherapy. Patients received lymphodepleting chemotherapy followed by infusion of autologous T cells transduced with the BiCAR construct. Treatment response and durability were assessed according to established criteria.\\n\\n**Results:** Twenty-four patients (median age 7 years, range 2-15 years) with a median of 2 prior lines of chemotherapy were enrolled. The BiCAR T-cell therapy demonstrated a high rate of objective response, with 19 patients (79%) achieving complete remission (CR) and 1 patient (4%) achieving partial remission.  The median duration of CR was 16 months (range 4-24 months). Five patients experienced serious adverse events, including cytokine release syndrome (CRS) and neurotoxicity, which were managed effectively.\\n\\n**Conclusions:** BiCAR T-cell therapy shows promising efficacy and manageable toxicity in children with chemotherapy-resistant B-ALL. Targeting both CD19 and CD22 with a single CAR construct may overcome antigen escape and improve long-term remission rates. Further investigation in larger clinical trials is warranted to confirm these findings.\\n\\n\\n**Key Findings:**\\n\\n* **High Response Rate:** The BiCAR T-cell therapy achieved a 79% complete response rate in children with chemotherapy-resistant B-ALL. This indicates a significant improvement over conventional chemotherapy options for this population.\\n* **Durable Remissions:** The median duration of complete remission was 16 months, suggesting the potential for long-term disease control with this treatment approach. \\n* **Manageable Toxicity:** While serious adverse events like CRS and neurotoxicity were observed, they were manageable with standard supportive care, highlighting the relative safety of the therapy.\\n* **Dual Antigen Targeting:** Targeting both CD19 and CD22 with a single CAR construct appears to be effective in preventing antigen escape, a common mechanism of relapse in CAR T-cell therapy.\\n\\n\\n**Medical Terminology and Concepts:**\\n\\n* **Chemotherapy-resistant pediatric B-cell acute lymphoblastic leukemia (B-ALL):** A type of blood cancer that affects children and has become resistant to standard chemotherapy treatments.\\n* **Immunotherapy:**  A type of cancer treatment that uses the body's own immune system to fight cancer cells.\\n* **Chimeric antigen receptor (CAR) T-cell therapy:** A type of immunotherapy where T-cells (a type of immune cell) are genetically engineered to express a chimeric antigen receptor that recognizes a specific antigen on cancer cells.\\n* **CD19 and CD22:** Proteins found on the surface of B-cell leukemia cells. They serve as targets for CAR T-cell therapy.\\n* **Bispecific CAR (BiCAR):** A CAR construct that targets two different antigens, in this case, both CD19 and CD22.\\n\\n\\nThis hypothetical paper provides a glimpse into a potential breakthrough in treating chemotherapy-resistant pediatric B-ALL. The use of dual antigen targeting with BiCAR T-cell therapy shows significant promise in achieving durable remissions and improving outcomes for this vulnerable patient population.\\n\" additional_kwargs={} response_metadata={'token_usage': {'completion_tokens': 799, 'prompt_tokens': 189, 'total_tokens': 988, 'completion_time': 1.452727273, 'prompt_time': 0.011712884, 'queue_time': 2.077783068, 'total_time': 1.464440157}, 'model_name': 'Gemma2-9b-It', 'system_fingerprint': 'fp_10c08bf97d', 'finish_reason': 'stop', 'logprobs': None} id='run--2c6d5c7f-1cb3-4ef2-872b-fb31c373e9cb-0' usage_metadata={'input_tokens': 189, 'output_tokens': 799, 'total_tokens': 988}\n",
      "   üìÑ Generated hypothetical paper (3866 characters)\n",
      "   üéØ Preview: ## CAR T-Cell Therapy with a Novel CD19/CD22 Bispecific Construct Demonstrates Durable Remissions in Chemotherapy-Resistant Pediatric B-Cell Acute Lymphoblastic Leukemia\n",
      "\n",
      "**Abstract**\n",
      "\n",
      "**Background:**...\n",
      "\n",
      "üß† STEP 3: Creating embeddings for hypothetical document...\n",
      "   üî¢ Generated 768 dimensional embedding vector\n",
      "   üìä Embedding sample: [0.04346198961138725, -0.04986504092812538, -0.05761146917939186, 0.05169515311717987, 0.07287552952766418]...\n",
      "\n",
      "üîç STEP 4: Retrieving documents using hypothetical embeddings...\n",
      "   üìö Retrieved 3 documents from medical knowledge base\n",
      "   ‚ö†Ô∏è Error in web search: 'str' object has no attribute 'get'\n",
      "   üìä Total retrieved documents: 3\n",
      "\n",
      "üí¨ STEP 5: Generating final medical research response...\n",
      "   ‚úÖ Generated comprehensive response (2997 characters)\n",
      "\n",
      "‚úÖ HyDE WORKFLOW COMPLETED\n",
      "================================================================================\n",
      "   - Generated hypothetical document (3866 chars)\n",
      "   - Retrieved 3 documents\n",
      "\n",
      "üìä KEY DIFFERENCES:\n",
      "   1. HyDE generates domain-specific hypothetical content\n",
      "   2. Better semantic matching through rich context\n",
      "   3. More relevant results for complex medical queries\n",
      "   4. Handles terminology variations better\n",
      "\n",
      "üéØ CONCLUSION:\n",
      "HyDE RAG is particularly powerful for medical research because:\n",
      "1. Medical queries are complex and domain-specific\n",
      "2. Hypothetical documents provide rich semantic context\n",
      "3. Better retrieval of relevant research papers\n",
      "4. Handles medical terminology and concepts effectively\n",
      "5. Bridges the gap between natural language queries and technical literature\n"
     ]
    }
   ],
   "source": [
    "# Example Usage and Demonstrations\n",
    "def run_medical_research_examples():\n",
    "    \"\"\"\n",
    "    Demonstrate HyDE RAG with various medical research scenarios.\n",
    "    \"\"\"\n",
    "    \n",
    "    # Initialize the HyDE system\n",
    "    hyde_system = HyDEMedicalRAG()\n",
    "    \n",
    "    # Test cases representing different types of medical queries\n",
    "    test_queries = [\n",
    "        {\n",
    "            \"query\": \"What are the latest immunotherapy approaches for treating pediatric acute lymphoblastic leukemia with resistance to conventional chemotherapy?\",\n",
    "            \"description\": \"Complex pediatric oncology query requiring recent research\"\n",
    "        },\n",
    "        {\n",
    "            \"query\": \"How effective is CAR-T cell therapy compared to traditional chemotherapy for relapsed B-cell lymphomas in elderly patients?\",\n",
    "            \"description\": \"Comparative effectiveness research question\"\n",
    "        },\n",
    "        {\n",
    "            \"query\": \"What are the current clinical trials investigating combination immunotherapy for triple-negative breast cancer?\",\n",
    "            \"description\": \"Current research and clinical trials query\"\n",
    "        }\n",
    "    ]\n",
    "    \n",
    "    # Run each test case\n",
    "    for i, test_case in enumerate(test_queries, 1):\n",
    "        print(f\"\\n{'#' * 20} EXAMPLE {i} {'#' * 20}\")\n",
    "        print(f\"Description: {test_case['description']}\")\n",
    "        print(f\"Query: {test_case['query']}\")\n",
    "        \n",
    "        # Execute HyDE workflow\n",
    "        result = hyde_system.run_hyde_workflow(test_case['query'])\n",
    "        \n",
    "        # Display results\n",
    "        print(f\"\\nüìã WORKFLOW SUMMARY:\")\n",
    "        print(f\"   Original Query: {result['original_query']}\")\n",
    "        print(f\"   Parsed Condition: {result['parsed_query'].condition}\")\n",
    "        print(f\"   Treatment Type: {result['parsed_query'].treatment_type}\")\n",
    "        print(f\"   Documents Retrieved: {len(result['retrieved_documents'])}\")\n",
    "        \n",
    "        print(f\"\\nüìù HYPOTHETICAL DOCUMENT PREVIEW:\")\n",
    "        print(result['hypothetical_document'][:500] + \"...\")\n",
    "        \n",
    "        print(f\"\\nüéØ FINAL RESPONSE:\")\n",
    "        print(result['final_response'])\n",
    "        \n",
    "        print(f\"\\n{'#' * 50}\")\n",
    "\n",
    "def compare_hyde_vs_traditional_rag():\n",
    "    \"\"\"\n",
    "    Demonstrate the difference between HyDE and traditional RAG approaches.\n",
    "    \"\"\"\n",
    "    \n",
    "    print(\"\\nüî¨ COMPARISON: HyDE vs Traditional RAG\")\n",
    "    print(\"=\" * 60)\n",
    "    \n",
    "    query = \"What are breakthrough immunotherapy treatments for chemotherapy-resistant pediatric leukemia?\"\n",
    "    \n",
    "    hyde_system = HyDEMedicalRAG()\n",
    "    \n",
    "    print(f\"Query: {query}\\n\")\n",
    "    \n",
    "    # Traditional RAG approach (direct query search)\n",
    "    print(\"üîç TRADITIONAL RAG APPROACH:\")\n",
    "    print(\"   - Searches directly with user query\")\n",
    "    print(\"   - May miss relevant papers due to vocabulary mismatch\")\n",
    "    print(\"   - Limited by exact keyword matching\")\n",
    "    \n",
    "    if hyde_system.medical_vectorstore:\n",
    "        traditional_results = hyde_system.medical_vectorstore.invoke(query)\n",
    "        print(f\"   - Retrieved {len(traditional_results)} documents\")\n",
    "        print(f\"   - Sample result: {str(traditional_results[0])[:200]}...\")\n",
    "    \n",
    "    print(\"\\nüß† HyDE RAG APPROACH:\")\n",
    "    print(\"   - First generates hypothetical ideal research paper\")\n",
    "    print(\"   - Uses rich medical terminology and context\")\n",
    "    print(\"   - Retrieves based on semantic similarity to ideal answer\")\n",
    "    \n",
    "    # Run HyDE workflow\n",
    "    hyde_result = hyde_system.run_hyde_workflow(query)\n",
    "    print(f\"   - Generated hypothetical document ({len(hyde_result['hypothetical_document'])} chars)\")\n",
    "    print(f\"   - Retrieved {len(hyde_result['retrieved_documents'])} documents\")\n",
    "    \n",
    "    print(\"\\nüìä KEY DIFFERENCES:\")\n",
    "    print(\"   1. HyDE generates domain-specific hypothetical content\")\n",
    "    print(\"   2. Better semantic matching through rich context\")\n",
    "    print(\"   3. More relevant results for complex medical queries\")\n",
    "    print(\"   4. Handles terminology variations better\")\n",
    "\n",
    "if __name__ == \"__main__\":\n",
    "    \"\"\"\n",
    "    Main execution - demonstrates HyDE RAG for medical research.\n",
    "    \"\"\"\n",
    "    \n",
    "    print(\"üè• HyDE RAG: Medical Research Assistant\")\n",
    "    print(\"=\" * 50)\n",
    "    print(\"This system demonstrates Hypothetical Document Embedding (HyDE)\")\n",
    "    print(\"for medical research queries. HyDE improves retrieval by first\")\n",
    "    print(\"generating hypothetical ideal research papers, then using them\")\n",
    "    print(\"to guide document retrieval.\")\n",
    "    print()\n",
    "    \n",
    "    # Run comprehensive examples\n",
    "    run_medical_research_examples()\n",
    "    \n",
    "    # Show comparison with traditional RAG\n",
    "    compare_hyde_vs_traditional_rag()\n",
    "    \n",
    "    print(\"\\nüéØ CONCLUSION:\")\n",
    "    print(\"HyDE RAG is particularly powerful for medical research because:\")\n",
    "    print(\"1. Medical queries are complex and domain-specific\")\n",
    "    print(\"2. Hypothetical documents provide rich semantic context\")\n",
    "    print(\"3. Better retrieval of relevant research papers\")\n",
    "    print(\"4. Handles medical terminology and concepts effectively\")\n",
    "    print(\"5. Bridges the gap between natural language queries and technical literature\")"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "langgraph",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.13.5"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
